DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: RE44459
|Title:||Method for lowering blood glucose|
|Abstract:||The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.|
|Inventor(s):||Kuczynski; Anthony L. (Mountain View, CA), Ayer; Atul Devdatt (Palo Alto, CA), Wong; Patrick S. L. (Palo Alto, CA)|
|Assignee:||Alza Corporation (Vacaville, CA)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent RE44459|
1. A method for treating hyperglycemia in a patient, wherein the method comprises administering to the patient a dosage form comprising 2.0 mg to 750 mg of a glipizide composition
that is administered at a dose of 10 ng to 25 mg per hour over an extended period of 24 hours, and wherein the method is characterized by administering the glipizide from a dosage form selected from the group consisting of an osmotic dosage form
comprising a semipermeable polymer permeable to the passage of fluid, and a diffusion dosage form comprising a polymer that permits diffusion of glipizide through the polymer..].
.[.2. A method for lowering blood sugar in the treatment of a diabetic patient, which method comprises orally administering to the patient an effective blood sugar lowering dose of a composition comprising glipizide and a pharmaceutically acceptable carrier, which blood sugar lowering dose is administered by a method selected from the group consisting of osmosis comprising a semipermeable membrane, diffusion through a polymer permeable to glipizide, and ion-exchange over time to produce the intended lowering of the blood sugar in the patient..].
.Iadd.3. A method for treating hyperglycemia in a patient, wherein the method comprises orally administering to the patient a once-a-day dosage form comprising 2.0 mg to 50 mg of a glipizide composition and wherein the method is characterized by administering the glipizide from an osmotic dosage form comprising polyethylene oxide, hydroxypropylmethylcellulose, cellulose acetate, and sodium chloride. .Iaddend.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.